Delgado Sigfrido 4/A

What Happened

• Sigfrido Delgado, Senior Vice President, Operations at Avanos Medical (AVNS), received two awards on March 13, 2026 totaling 53,668 time‑based restricted share units (TRSUs): 15,886 TRSUs and 37,782 TRSUs. Both were awarded at $0.00 (no cash paid) and are recorded as acquisitions (award/derivative). The filing on April 1, 2026 is an amended Form 4 that corrects a prior calculation error related to awards issued on March 13, 2026.

Key Details

• Transaction dates/prices: March 13, 2026; price $0.00 for both awards (awards, not open‑market purchases).
• Grant totals: 15,886 TRSUs (F1) + 37,782 TRSUs (F2) = 53,668 TRSUs.
• Vesting (per footnotes):
  • F1 (15,886): vests 1/3 on Mar 13, 2027, 1/3 on Mar 13, 2028, and 1/3 on Mar 13, 2029.
  • F2 (37,782): vests 30% on Mar 13, 2027, 30% on Mar 13, 2028, and 40% on Mar 13, 2029.
• Nature of security: TRSUs are derivative awards that represent the economic equivalent of one share of common stock and convert to shares (or cash equivalent) upon vesting.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing note: This is a Form 4/A (amendment) filed Apr 1, 2026 to correct the calculation of awards issued Mar 13, 2026; the filing date is after the transaction date (i.e., later than the typical 2‑business‑day Section 16 reporting window).

Context

• These are time‑based restricted units (long‑term incentive awards), not open‑market purchases or sales; such awards are routine compensation and vest over multiple years.
• Because the awards vest in future installments, they do not represent immediately tradable shares. The amended filing corrects prior reporting but does not by itself indicate a change in insider sentiment.